Boc-R-3-Amino-3-(3-trifluoromethyl-phenyl)-propionic Acid: A Key Intermediate for Pharmaceutical Innovation

Discover the power of Boc-R-3-Amino-3-(3-trifluoromethyl-phenyl)-propionic acid, a high-purity intermediate crucial for advanced pharmaceutical research and the development of next-generation therapeutics. Explore its applications in peptide synthesis and medicinal chemistry.

Get a Quote & Sample

Key Advantages for Your Research and Development

Exceptional Purity for Reliable Results

Our Boc-R-3-Amino-3-(3-trifluoromethyl-phenyl)-propionic acid is guaranteed with high purity (≥99% HPLC), essential for reproducible research and successful drug formulation. As a reputable manufacturer, we ensure stringent quality control.

Optimized for Pharmaceutical Applications

The integration of the Boc protecting group and the trifluoromethyl substituent makes this compound highly suitable for complex synthetic routes in medicinal chemistry and drug discovery, offering a superior building block for your pipeline.

Facilitates Novel Therapeutic Development

Explore new therapeutic avenues by incorporating this versatile intermediate into your drug design. It's instrumental in creating compounds with improved biological activity and stability, meeting the demands of modern pharmaceutical research.

Diverse Applications in Pharmaceutical and Chemical Synthesis

Pharmaceutical Development

Serve as a critical intermediate in the synthesis of novel pharmaceuticals, particularly for drugs targeting neurological disorders, leveraging its unique structural properties.

Peptide Synthesis

Widely used in solid-phase peptide synthesis, enabling researchers to construct peptides with enhanced functionalities and therapeutic potential.

Medicinal Chemistry

Act as a key building block in medicinal chemistry for designing and optimizing lead compounds, improving their pharmacokinetic properties and efficacy.

Bioconjugation

Applied in bioconjugation techniques to attach biomolecules to drugs or imaging agents, crucial for developing targeted therapies.